ArticleSaudi journal of medicine & medical sciences
Outcomes of Dupilumab Treatment in Refractory Eosinophilic Esophagitis: A Retrospective Cohort Study from Saudi Arabia.
Article in Saudi journal of medicine & medical sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dupilumab, an IL-4 and IL-13 inhibitor, has been approved for the treatment of eosinophilic esophagitis (EoE), a type two inflammatory disease. Few studies from Saudi Arabia have reported the prevalence and characteristics of EoE and treatment response, particularly dupilumab. Objective: To report dupilumab treatment outcomes in adult Saudi patients with EoE. Methods: This retrospective cohort study included all adult treatment-refractory EoE patients who received subcutaneous dupilumab 300 mg between January 2023 and November 2024 at a tertiary hospital in Riyadh, Saudi Arabia. Patient demographics, clinical characteristics, and procedural data were recorded. The primary outcome was to evaluate clinical response to dupilumab, and the secondary outcome was to compare Endoscopic Reference Score (EREFS) and histological outcome following dupilumab treatment with baseline assessments. Results: A total of 22 patients were included (mean age: 29.7 ± 11.2 years; male: 63.6%). At baseline, most had dysphagia to solids (95.5%) and type 2 inflammatory comorbidities (72.7%). In addition, all patients were on PPIs and had >15 eosinophils/hpf on histology. After dupilumab treatment, 91% (95% CI: 74.3%-97.9%) achieved symptomatic improvement. Post-dupilumab esophagogastroduodenoscopies were performed in 21 patients (median duration: 9.5 months), and most showed reduced inflammatory features. EREFS scores decline from a median of 3 units at baseline to 1 unit after dupilumab treatment ( Conclusion: In this cohort study of Saudi adults with refractory eosinophilic esophagitis, dupilumab treatment was associated with significant clinical, endoscopic, and histological improvements, in addition to having an acceptable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.